References
- Andreasen NC, Nopoulos P, Schultz S, Miller D, Gupta S, Swayze V, Flaum M. (1994). Positive and negative symptoms of schizophrenia: past, present, and future. Acta Psychiatr Scand Suppl 384:51–59.
- Citrome L. (2011a). Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin Schizophr Relat Psychoses 4:251–257.
- Citrome L. (2011b). Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 65:189–210.
- Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095.
- Enomoto T, Ishibashi T, Tokuda K, Ishiyama T, Toma S, Ito A. (2008). Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res 186:197–207.
- FDA U. (2001). Guidance for industry: bioanalytical method validation. Rockville, MD: CDER.
- Gründer G, Hippius H, Carlsson A. (2009). The ‘atypicality’ of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov 8:197–202.
- Haddad P. (2005). Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol (Oxford) 19:16–27.
- Houston JB, Carlile DJ. (1997). Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 29:891–922.
- Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M. (2010). Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 334:171–181.
- Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y. (2007). Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 572:160–170.
- Koo TS, Kim SJ, Lee J, Ha DJ, Baek M, Moon H. (2011). Quantification of lurasidone, an atypical antipsychotic drug, in rat plasma with high performance liquid chromatography with tandem mass spectrometry. Biomed Chromatogr [Epub ahead of print, doi: 10.1002/bmc.1625]
- Kusuhara H, Suzuki H, Terasaki T, Kakee A, Lemaire M, Sugiyama Y. (1997). P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J Pharmacol Exp Ther 283:574–580.
- Lee KR, Maeng HJ, Chae JB, Chong S, Kim DD, Shim CK, Chung SJ. (2010). Lack of a primary physicochemical determinant in the direct transport of drugs to the brain after nasal administration in rats: potential involvement of transporters in the pathway. Drug Metab Pharmacokinet 25:430–441.
- Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41.
- Lieberman JA. (1993). Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. Br J Psychiatry Suppl 7–18.
- Meltzer HY. (1999). Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions. Biol Psychiatry 46:1321–1327.
- Meyer JM, Loebel AD, Schweizer E. (2009). Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 18:1715–1726.
- Pang KS, Rowland M. (1977). Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625–653.
- van Os J, Kapur S. (2009). Schizophrenia. Lancet 374:635–645.